1. A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
- Author
-
Seung-hwan Jeong, Sang Eun Yeon, Su Youn Kim, Tae Gyun Kwon, Seong Soo Jeon, Young Deuk Choi, Dongdeuk Kwon, Byung Ha Chung, Sung-Hoo Hong, Byung Hoon Kim, Hyo Jin Lee, Sang Joon Shin, Woo Suk Choi, Sung Woo Park, Taek Won Kang, Seok Joong Yun, Jin Seon Cho, See Min Choi, Na-Ri Lee, and Cheol Kwak
- Subjects
abiraterone ,prostate cancer ,prostate-specific antigen ,real-world data ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Purpose: The proper treatment sequence for administering abiraterone acetate plus prednisolone (AAP) and chemotherapeutic agents has not yet been elucidated for metastatic castration-resistant prostate cancer (mCRPC). Hence, this study evaluated the effectiveness and safety of AAP in pre- and post-chemotherapy settings using real-world data. Materials and Methods: This prospective, multicenter, open-label, observational study included 506 patients with mCRPC. Patients were classified according to the timing of chemotherapy into pre- and post-chemotherapy groups. The effectiveness and safety of AAP were compared between the groups; the prostate-specific antigen (PSA) response, PSA progression-free survival, and radiologic progression-free survival were assessed; and adverse drug reactions were recorded. Results: Among the included patients, 319 and 187 belonged to the pre- and post-chemotherapy groups, respectively. Risk classification was similar between the two groups. The PSA response was 61.8% in the pre-chemotherapy group and 39.0% in the post-chemotherapy group (p
- Published
- 2023
- Full Text
- View/download PDF